Scheen, A.J., Paquot, N., Lefehvre, P.J., Etiologie et physiopathahgie du diebete non insulino dependent. Encyclopédie médico-chirurgicale (Paris-France) (1995) Endocrinologie-Nutrition, 10-366 D-10, 7p
Scheen, A.J., Lefèbvre, P.J., Pathophysiology of type 2 diabetes (1996) Handbook of Experimental Pharmacology, Oral Antidiabetics, pp. 7-42. , Kuhlmann J, Puls W, editors. Berlin : Springer Verlag
Scheen, A.J., Paquot, N., Lefèbvre, P.J., Approches thérapeutiques des anomalies de la boucle de régulation glucose-insuline chez le patient diabétique (1992) Méd et Hyg, 50, pp. 2088-2093
Lefèbvre, P.J., Scheen, A.J., Improving the action of insulin (1995) Clin Invest Med, 18, pp. 340-347
Reaven, C.M., Role of insulin resistance in human disease (1988) Diabetes, 37, pp. 1595-1607
DeFronzo, R.A., Ferrannini, E., Insulin resistance : A mutltifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease (1991) Diabetes Care, 14, pp. 173-194
Scheen, A.J., Le syndrome plurimétabolique associé à l'insulinorésistance ou syndrome X: Actualisation après 10 ans (1997) Diabétologie et Facteurs de Risque, 3, pp. 254-258
Scheen, A.J., Drug treatment of noninsulin-dependent diabetes mellitus in the 1990s: Achievements and future developments (1997) Drugs, 54, pp. 355-368
Scheen, A.J., Lefèbvre, P.J., La metformine : Des effets métaboliques aux indications thérapeutiques (1993) Méd et Hyg, 51, pp. 1993-1998
Scheen, A.J., Paquot, N., Letiexhe, M.R., Lefèbvre, P.J., A propos de quelques utilisations non conventionnelles de la metformine (1997) Méd et Hyg, 55, pp. 1492-1494
Irzucchi, S.E., Maggs, D.G., Spollett, G.R., Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus (1998) N Engl J Med, 338, pp. 867-872
Hofmann, C.A., Colca, J.R., New oral azolidinedione antidiabetic agents act as insulin sensitizers (1992) Diabetes Care, 15, pp. 1675-1678
Henry, R.R., Thidinedioms (1997) Endocrinol Metab Clin North Am, 26, pp. 553-573
Kaneko, T., Troglitazone (CS-045): A new antidiabetic agent (1997) Horm Metab Res, 29, pp. 203-213
Spencer, C.M., Markham, A., Troglitaznne (1997) Drugs, 54, pp. 89-101
Saltiel, A.R., Okfsky, J.M., Thiazolidinediones in the treatment of insulin resistante and type II diabetes (1996) Diabetes, 45, pp. 1661-1669
Spiegelman, B.M., PPAR-gamma : Adipogenic regulator and thiazolidinedione receptor (1998) Diabetes, 47, pp. 507-514
Nolan, J.J., Ludvik, B., Beerdsen, P., Improvement in glucose tole- Rance and insulin resistance in obese subjects treated with troglitazone (1994) N Engl J Med, 131, pp. 1188-1193
Antonucci, T., Whitcomb, R., McLain, K., Lockwood, D., Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone (1997) Diabetes Care, 20, pp. 188-193
Berkawitz, K., Peters, R., Kjos, S.L., Effect of troglitazone on insulin sensitivity and pancreatic B-cell function in women at high risk for NIDDM (1996) Diabetes, 45, pp. 1572-1579
Mimura, K., Umeda, A., Hiramatsu, S., Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes (1994) Diabetic Med, 11, pp. 685-691
Petrie, J., Small, M., Connell, J., «Glitazones», a prospect for non-insnlin-dependent diabetes (1997) Lancet, 349, pp. 70-71
Scheen, A.J., Lefebvre, P.J., Oral antidiabetic agents: A guide to selection (1998) Drugs, 55, pp. 225-236
Kumar, S., Boulton, A.J.M., Beck-Nielsen, H., Troglitazone. An insulin action enhancer, improves metabolic control in NIDDM patients (1996) Diabetohgia, 39, pp. 701-709. , for the Troglitazone study group
Iwamoto, Y., Kosaka, K., Kuzuya, T., Effect of combination therapy of troglitazone and stdphonylureas in patients with type 2 diabetes who were poorly controlled by sulphonylurea therapy alone (1996) Diabetic Med, 13, pp. 365-370
Schwartz, S., Raskin, P., Fonseca, V., Effect of troglitazone in insulin-treated patients with type II diabetes mellitus (1998) N Engl J Med, 338, pp. 861-866
Ghazzi, M.N., Perez, J.E., Antonucci, T.K., Cardiac and glycemic benefits of troglitazone treatment in NIDDM (1997) Diabetes, 46, pp. 433-439
Prigeon, R.L., Kahn, S.E., Porte Jr., D., Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus (1998) J Clin Endocrinol Metab, 83, pp. 819-823
Watkins, P.B., Whitcomb, R.W., Hepatic dysfunction associated with troglitazone (1998) N Engl J Med, 338, pp. 916-917
Imura, H., A novel antidiabetic drug, troglitazone - Reason for hope and concern (1998) N Engl J Med, 338, pp. 908-909
